Type of study—number of subjects—study population

Therapeutic modalities

1. Open prospective study
2. n = 10 subjects
3. Cobalamin deficiency related to food-cobalamin malabsorption

Oral cyanocobalamin: 650 µg/day during 3 months

1. Normalisation of serum cobalamin levels in 80% of subjects
2. Significant 1.9g/dl increase in Hb and significant 7.8fl decrease in ECV
3. Improvement of clinical abnormalities in 20% of subjects

[31]

1. Open prospective study
2. n = 30
3. Cobalamin deficiency related to food-cobalamin malabsorption

Oral cyanocobalamin: 250 to 1000 µg/day

during 1 month

1. Normalisation of serum cobalamin levels in 87% of the subjects
2. Significant 0.6 g/dl increase in Hb and significant 3fl decrease in ECV; normalisation of Hb and ECV in 54% and 100% of the subjects, respectively
3. Dose effect (dose >500 µg/day more effective)

[30]

1. Open prospective study
2. n = 30
3. Cobalamin deficiency related to food-cobalamin malabsorption

Oral cyanocobalamin: 125 to 1000 µg/day during 1 week

1. Normalisation of serum cobalamin levels in all patients treated with >250 µg/day
2. Dose effect (dose >500 µg/day more effective)

[32]

1. Retrospective study
2. n=31
3. Cobalamin deficiency related to food-cobalamin malabsorption (n=20) and pernicious anaemia (n=10)

Oral cyanocobalamin: 125 to 1000 µg/day

during at least 3 month

1. Significant 161.6 pg/mL increase of serum cobalamin levels in food-cobalamin group and 136.7 pg/mL in pernicious anaemia
2. Improvement of haematological abnormalities in 90.1% of subjects

[34]